For your patients with moderate to very severe COPD, long-acting bronchodilator (LABD) therapy may be an appropriate option. In fact, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends LABDs as a standard of care for COPD maintenance.1
But improper administration could impact your patients’ COPD treatment goals.2,3
References: 1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017:1-139. 2. Fulvio B, Lavorini F, Blasi F, Baiardini I, Canonica GW. Switching treatments in COPD: implications for costs and treatment adherence. Int J Chron Obstruct Pulmon Dis. 2015;10:2601-2608. 3. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11(149):1-14.